Patents by Inventor Francesco Della Valle

Francesco Della Valle has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220304954
    Abstract: The present invention relates to a method of treating a COVID-19 infection by administering an effective amount of an endogenous compound devoid of significant toxicity. In particular, the present invention relates to a method of treating a patient affected by COVID-19 infection comprising administering an effective amount of a mixture of ultra-micronized palmitoylethanolamide and micronized palmitoylethanolamide to said patient.
    Type: Application
    Filed: March 26, 2021
    Publication date: September 29, 2022
    Applicant: Epitech Group S.p.A.
    Inventors: Francesco Della Valle, Maria Federica Della Valle, Gabriele Marcolongo, Giuliano Claps, Chiara Gomiero, Vito Safina
  • Publication number: 20220304956
    Abstract: The present invention relates to a method of treating a COVID-19 infection by administering an effective amount of an endogenous compound devoid of significant toxicity. In particular, the present invention relates to a method of treating a patient affected by COVID-19 infection comprising administering an effective amount of a mixture of ultra-micronized palmitoylethanolamide and micronized palmitoylethanolamide to said patient.
    Type: Application
    Filed: February 7, 2022
    Publication date: September 29, 2022
    Applicant: Epitech Group S.p.A.
    Inventors: Francesco DELLA VALLE, Maria Federica DELLA VALLE, Gabriele MARCOLONGO, Giuliano CLAPS, Chiara GOMIERO, Vito SAFINA, Annalisa NOCE, Salvatore CUZZOCREA, Giuseppe ESPOSITO
  • Publication number: 20220296541
    Abstract: Described herein is a use of N-palmitoylethanolamide in the context of an antitumor therapy, in particular, a use of Palmitoylethanolamide in the prevention of colorectal carcinoma, adenomatous polyps, and/or pre-neoplastic ACF lesions. Also described herein are palmitoylethanolamide for use in the antineoplastic therapy of colorectal carcinoma, in which the palmitoylethanolamide exerts a selective antiproliferative action on tumor cells and not on healthy cells.
    Type: Application
    Filed: March 10, 2022
    Publication date: September 22, 2022
    Inventors: Francesco DELLA VALLE, Maria Federica DELLA VALLE, Chiara GOMERIO, Francesca BORRELLI, Raffaele CAPASSO, Angelo Antonio IZZO, Ester PAGANO, Barbara ROMANO
  • Publication number: 20210308160
    Abstract: The present invention relates to an N-palmitoyl-D-glucosamine-based composition in a micronized form, optionally in combination with Curcumin. In particular, the present invention relates to N-palmitoyl-D-glucosamine in a micronized or co-micronized form with Curcumin. Such a product can be formulated in human or veterinary pharmaceutical compositions, dietetic products, food supplements, or foods for special medical purposes (FSMP), or in feeds, or nutritional supplements for animals for the treatment of chronic systemic inflammatory diseases, in humans and animals, resulting from dysfunctions of epithelia and synovial membranes.
    Type: Application
    Filed: June 17, 2021
    Publication date: October 7, 2021
    Applicant: Innovet Italia S.R.L.
    Inventors: Francesco Della Valle, Maria Federica Della Valle, Gabriele Marcolongo, Sofia Parrasia, Salvatore Cuzzocrea
  • Publication number: 20210169828
    Abstract: Described herein are pharmaceutical compositions containing Adelmidrol. In particular, the Adelmidrol is used in the treatment of diseases characterized by insufficient specific agonism of the PPAR-gamma receptor in humans or animals, more particularly in the treatment of articular chondropathies of mechanical, toxic, iatrogenic, degenerative origin, or associated with inflammatory phenomena mainly related to organs and tissues not belonging to the osteoarticular system; fibrogenesis of the articular cartilages; chronic inflammatory bowel diseases (IBDs) such as Crohn's disease and ulcerative colitis; Irritable Bowel Syndrome (IBS); diseases characterized by an abnormal fibrosis of the connective tissue, such as systemic sclerosis, particularly of the skin and lung; eye disorders characterized by angiogenesis, fibrosis, inflammation and oxidative stress.
    Type: Application
    Filed: February 11, 2021
    Publication date: June 10, 2021
    Applicant: Epitech Group S.P.A.
    Inventors: Francesco Della Valle, Maria Federica Della Valle, Salvatore Cuzzocrea
  • Publication number: 20210060047
    Abstract: Described herein is a composition based on N-palmitoyl-ethanolamide and Rutin in co-micronized form. In particular, a composition includes a mixture of palmitoyl-ethanolamide (PEA) and Rutin in co-micronized form in which the PEA/Rutin ratio is between 10:1 and 1:1. Pharmaceutical formulations for the treatment of humans and animals are also described. The composition is useable for the treatment of diseases of arteries and arterioles.
    Type: Application
    Filed: August 25, 2020
    Publication date: March 4, 2021
    Inventors: Francesco DELLA VALLE, Maria Federica DELLA VALLE, Gabriele MARCOLONGO, Salvatore CUZZOCREA, Vito SAFINA
  • Patent number: 10441559
    Abstract: A method of controlling the inflammatory and/or neuropatic pain of various origins by administering a pharmaceutical composition containing palmitoylethanolamide, to a human or animal patient. In particular, the present invention relates to the administration of a pharmaceutical composition comprising palmitoylethanolamide (PEA) and L-acetylcarnitine (LAC), optionally in addition with an antioxidant compound, such as a polyphenol, alpha-lipoic acid, or L-acetylcysteine to a patient.
    Type: Grant
    Filed: May 24, 2017
    Date of Patent: October 15, 2019
    Assignee: Epitech S.P.A.
    Inventors: Francesco Della Valle, Maria Federica Della Valle
  • Publication number: 20190290609
    Abstract: It is the object of the present invention a pharmaceutical composition for use in humans or animals containing N-palmitoylethanolamide for the control of the inflammatory and/or neuropathic pain of various origin. In particular, the present invention relates to a pharmaceutical composition comprising palmitoylethanolamide (PEA and L-acetylcarnitine (LAC), optionally with in addition an antioxidant compound such as a polyphenol, alpha-lipoic acid, and L-acetylcysteine.
    Type: Application
    Filed: June 10, 2019
    Publication date: September 26, 2019
    Inventors: Francesco DELLA VALLE, Maria Federica DELLA VALLE
  • Publication number: 20190290669
    Abstract: The present invention relates to an N-palmitoyl-D-glucosamine-based composition in a micronized form, optionally in combination with Curcumin. In particular, the present invention relates to N-palmitoyl-D-glucosamine in a micronized or co-micronized form with Curcumin. Such a product can be formulated in human or veterinary pharmaceutical compositions, dietetic products, food supplements, or foods for special medical purposes (FSMP), or in feeds, or nutritional supplements for animals for the treatment of chronic systemic inflammatory diseases, in humans and animals, resulting from dysfunctions of epithelia and synovial membranes.
    Type: Application
    Filed: March 20, 2019
    Publication date: September 26, 2019
    Applicant: Innovet Italia S.R.L.
    Inventors: Francesco Della Valle, Maria Federica Della Valle, Gabriele Marcolongo, Sofia Parrasia, Salvatore Cuzzocrea
  • Publication number: 20190224145
    Abstract: Described herein is the use of Adelmidrol in the treatment of epithelial dysfunctions. In particular, described herein is Adelmidrol for use in the treatment of epithelial tissue dysfunctions in a human being or animal, wherein said Adelmidrol causes an increase of the endogenous levels of Palmitoylethanolamide without inhibiting the activity of the Palmitoylethanolamide-degrading FAAH and NAAA enzymes.
    Type: Application
    Filed: April 4, 2019
    Publication date: July 25, 2019
    Applicant: Epitech Group S.p.A.
    Inventors: Maria Federica Della Valle, Francesco Della Valle, Vincenzo Di Marzo, Stefania Petrosino, Barbara Costa, Gabriele Marcolongo, Daniele Grassi
  • Patent number: 9801836
    Abstract: Described herein are pharmaceutical compositions for human or animal use containing N-palmitoylethanolamide as an analgesic in combination with opioids. In particular, the compositions include palmitoylethanolamide in non-micronized form, in micronized form (PEA-m), in ultra-micronized form (PEAum) or mixtures thereof, for use in humans or animals in combination with an opioid in the treatment of pain conditions, wherein said palmitoylethanolamide is administered separately, sequentially, or in combination with said opioid.
    Type: Grant
    Filed: May 13, 2015
    Date of Patent: October 31, 2017
    Assignee: Epitech Group S.r.l.
    Inventors: Francesco Della Valle, Maria Federica Della Valle, Lorenzo Di Cesare Manelli, Carla Ghelardini
  • Publication number: 20170252314
    Abstract: A method of controlling the inflammatory and/or neuropatic pain of various origins by administering a pharmaceutical composition containing palmitoylethanolamide, to a human or animal patient. In particular, the present invention relates to the administration of a pharmaceutical composition comprising palmitoylethanoiamide (PEA) and L-acetylcarnitine (LAC), optionally in addition with an antioxidant compound, such as a polyphenol, alpha-lipoic acid, or L-acetylcysteine to a patient.
    Type: Application
    Filed: May 24, 2017
    Publication date: September 7, 2017
    Inventors: Francesco DELLA VALLE, Maria Federica DELLA VALLE
  • Publication number: 20170209395
    Abstract: Described herein is the use of Adelmidrol in the treatment of epithelial dysfunctions. In particular, described herein is Adelmidrol for use in the treatment of epithelial tissue dysfunctions in a human being or animal, wherein said Adelmidrol causes an increase of the endogenous levels of Palmitoylethanolamide without inhibiting the activity of the Palmitoylethanolamide-degrading FAAH and NAAA enzymes.
    Type: Application
    Filed: April 7, 2017
    Publication date: July 27, 2017
    Applicant: Epitech Group S.r.l.
    Inventors: Maria Federica Della Valle, Francesco Della Valle, Vincenzo Di Marzo, Stefania Petrosino, Barbara Costa, Gabriele Marcolongo, Daniele Grassi
  • Patent number: 9668986
    Abstract: It is the object of the present invention a composition containing an N-acyl-ethanolamine in a solubilized form, particularly a solution for ophthalmic, intra-articular or intravesical use. Particularly, the present invention relates to a water-soluble composition comprising one or more N-acylethanolamines (NAE) in the form of an inclusion complex in methyl-beta-cyclodextrin (M?CD).
    Type: Grant
    Filed: March 2, 2015
    Date of Patent: June 6, 2017
    Assignee: EPITECH GROUP S.R.L.
    Inventors: Francesco Della Valle, Sebastiano Mangiafico, Maria Federica Della Valle
  • Publication number: 20170119706
    Abstract: Described herein are pharmaceutical compositions containing Adelmidrol. In particular, the Adelmidrol is used in the treatment of diseases characterized by insufficient specific agonism of the PPAR-gamma receptor in humans or animals, more particularly in the treatment of articular chondropathies of mechanical, toxic, iatrogenic, degenerative origin, or associated with inflammatory phenomena mainly related to organs and tissues not belonging to the osteoarticular system; fibrogenesis of the articular cartilages; chronic inflammatory bowel diseases (IBDs) such as Crohn's disease and ulcerative colitis; Irritable Bowel Syndrome (IBS); diseases characterized by an abnormal fibrosis of the connective tissue, such as systemic sclerosis, particularly of the skin and lung; eye disorders characterized by angiogenesis, fibrosis, inflammation and oxidative stress.
    Type: Application
    Filed: October 24, 2016
    Publication date: May 4, 2017
    Applicant: Epitech Group S.P.A.
    Inventors: Francesco DELLA VALLE, Maria Federica DELLA VALLE, Salvatore CUZZOCREA
  • Patent number: 9522192
    Abstract: The synthesis of a series of Polyethylene glycol conjugates (esters and carbonates) of PEA and its analogous acylethanolamides, have higher water solubility and good hydrophilic/lipophilic balance, resulting in (i) improved accumulation in tissues (particularly skin and mucosae), (ii) prolonged release, and (iii) increased bioavailability. Improvement of PEA and analogous acylethanolamides levels in the tissues—particularly in the skin and mucosae—and their prolonged release is due to the improved bioavailability of related conjugates. Conjugates are able to extend the time frame in which PEA and analogous acylethanolamides exert their pharmacological effects.
    Type: Grant
    Filed: December 11, 2013
    Date of Patent: December 20, 2016
    Assignee: EPITECH GROUP S.r.l.
    Inventors: Antonio Calignano, Giuseppe D'Agostino, Sonia Laneri, Rosaria Meli, Carmine Ostacolo, Roberto Russo, Antonia Sacchi, Diana Tronino, Francesco Della Valle, Maria Federica Della Valle, Gabriele Marcolongo
  • Patent number: 9512091
    Abstract: The present invention regards compositions and methods for the modulation of amidases capable of hydrolyzing N-acylethanolamines useable in the therapy of inflammatory diseases. In particular, the present invention regards a compound of general formula (I): enantiomers, diastereoisomers, racemes and mixtures, polymorphs, salts, solvates thereof, wherein: (a) R is a linear alkyl radical having 13 to 19 carbon atoms or alkenyl radical having 13 to 19 carbon atoms carrying a double bond; (b) X is 0 or S; (c) Y is a 2 or 3 carbon atom alkylene residue, optionally substituted with one or two groups equal or different from each other and selected from among the group consisting of: —CH3, —CH2OH, —COOCH3, —COOH. Y may preferably be: —CH2—CH2—, —CH2—CH2—CH2—, CH(CH3)—CH2—, —CH2—CH(CH3)—, —CH2—C(CH3)2—, —CH2—CH(CH2OH)—, —CH2—C((CH2OH)2)—, —CH?CH—, —CH2—CH(COOCH3)—, —CH2—CH(COOH)—, for use as a medicine.
    Type: Grant
    Filed: February 17, 2012
    Date of Patent: December 6, 2016
    Assignee: Epitech Group S.r.l.
    Inventors: Francesco Della Valle, Maria Federica Della Valle, Gabriele Marcolongo, Vincenzo Di Marzo, Salvatore Cuzzocrea
  • Patent number: 9402818
    Abstract: A therapy for renal diseases, in particular renal diseases, which develop in diabetic patients or patients who have been subjected to a treatment with an antitumor chemotherapy such as a platinum derivative and more generally cytotoxic drugs at renal level for treating of neoplastic diseases. More particularly, palmitoylethanolamide and diethanolamide of fumaric acid are used in the treatment of renal diseases, in particular those caused by dysmetabolic diseases or by toxic or chemotherapy agents, such as platinum derivatives. Palmitoylethanolamide is used preferably in micronized or ultra-micronized form. Diethanolamide of fumaric acid is used preferably in aqueous solution.
    Type: Grant
    Filed: November 7, 2014
    Date of Patent: August 2, 2016
    Assignee: Epitech Group S.r.l.
    Inventors: Francesco Della Valle, Raffaele Migliaccio, Maria Federica Della Valle
  • Patent number: 9399031
    Abstract: A therapy for renal diseases characterized by alterations of the kidney function, such as Chronic Kidney Disease (CKD), acute and chronic renal impairment, and renal diseases that develop in diabetic patients or in patients who underwent an anticancer chemotherapic treatment with a platinum derivative. The invention is a combination of compounds selected from mono- or diamide of a C12-C20 monocarboxylic acid, saturated or monounsaturated, or a C4-C14 dicarboxylic acid, saturated or monounsaturated, with an aminoalkanol, and compounds selected from Silymarin, derivatives thereof or conjugates or complexes thereof, for use in the treatment of renal diseases.
    Type: Grant
    Filed: July 3, 2014
    Date of Patent: July 26, 2016
    Assignee: Epitech Group S.r.l.
    Inventors: Francesco Della Valle, Maria Federica Della Valle, Gabriele Marcolongo, Salvatore Cuzzocrea
  • Publication number: 20160045529
    Abstract: The described herein is a pharmaceutical composition for use in humans or animals containing N-palmitoylethanolamide and Cytidinediphosphocholine for the treatment of pathologies of the Central Nervous System of a traumatic, vascular, degenerative nature associated with neurodegeneration. The pharmaceutical composition containing palmitoylethanolamide (PEA) and Cytidinediphosphocholine (CDP-Choline or Citicoline), possibly with the addition of an antioxidant compound such as for example a polyphenol, alpha-lipoic acid or L-acetylcysteine.
    Type: Application
    Filed: August 12, 2015
    Publication date: February 18, 2016
    Applicant: EPITECH GROUP S.R.L.
    Inventors: Francesco Della Valle, Maria Federica Della Valle, Gabriele Marcolongo, Salvatore Cuzzocrea